ArticleInternational journal of hematology2023
Stem cell regulation and dynamics in myeloid malignancies.
Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- CanPharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and tissue homeostasis, and are now recognized as an important driver for cancer development. Regarding spatiotemporal factors, Dr. Inoue reviewed the role of extracellular vesicles in leukemic stem cell niches. As some cancers develop preferentially in infancy or old age, Dr. Osato discussed the time-specific development of leukemia involving the RUNX1-ETO mutation, which is often found in leukemia in adolescents and young adults. Recent studies on hematopoietic development have shown that hematopoietic stem cells do not generate multipotent progenitor cells, but that these cells develop in parallel. We hope that reconsideration of the definition of leukemic stem cells and their origin will help us understand the regulatory mechanisms of these cells, but also enable us to develop future therapies by targeting factors that regulate the leukemic stem cell and the niche.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.